• Optimizing ART With Novel HIV Agents

  • Aug 16 2024
  • Duración: 13 m
  • Podcast

Optimizing ART With Novel HIV Agents

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • In this episode, Gregory Huhn, MD, MPHTM, presents a case study of a person with a long HIV treatment history, exploring when and how to consider agents with novel mechanisms of action.

    Listen as he discusses:

    • The importance of engaging with patients to understand their perspectives and improve their satisfaction with their HIV care
    • Options in people with multiclass resistance
    • Studies of agents with novel mechanisms of action:
      • BRIGHTE (fostemsavir)
      • TMB-301/-311 (ibalizumab)
      • CAPELLA (lenacapavir)

    Faculty

    ​​Gregory Huhn, MD, MPHTM,
    Interim Chief, Division of Infectious Diseases
    Senior Director of HIV Services
    Cook County HIV Integrated Programs
    Interim Medical Director, The RMR CORE Center
    Professor, Division of Infectious Diseases
    Rush University Medical Center
    Chicago, Illinois

    Follow along with the slides.
    https://bit.ly/4fHmxg5

    Get access to all of our new podcast episodes. Subscribe to the CCO Infectious Disease podcast on Apple Podcasts, Google Podcasts, or Spotify.

    Más Menos
activate_Holiday_promo_in_buybox_DT_T2
Más Menos

Lo que los oyentes dicen sobre Optimizing ART With Novel HIV Agents

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles